FDA approves Mercado PD-1 tumor immunotherapy Keytruda for treatment of hepatocellular carcinoma patients

recently, Mercado announced that the U.SFDA(approved its PD-1 tumor immunotherapy Keytruda (Chinese commodity name: Creeda, generic name: Pablo Pearlmono) a new indication for patients with hepatocellular carcinoma (HCC) who have previously received targeteddrug(Sorafeni)this approval is based on accelerated approval of tumor remission and mitigation persistence data, further approval will depend on the validation and description of clinical benefits in confirmed clinical studiesat the end of last month, the FDA also approved Keytruda combined chemotherapy (caplatinum-purple alcohol or albumin-combined yew alcohol (nab-paclitaxel)) for first-line treatment for patients with metastatic squamous nSCLC, regardless of the expression status of tumor PD-L1This approval makes Keytruda the first first-line treatment of scaly NSCLC regardless of the tumor PD-L1 expression status of PD-1 tumor immunotherapythe studythe approval of Keytruda HCC indications is based on data from the KEYNOTE-224 studythe study was a single set of open label studies that assessed the efficacy and safety of Keytruda treatment in 104 patients who were treated with sorafenib during or after treatment for progressorin the disease or intolerant of sorafenibdata show that the total remission rate (ORR) for Keytruda treatment was 17% (95% CI: 11-26), the total remission rate was 1%, and the partial remission rate was 16%In patients with remission (n-18), 89% of patients with remission duration (DOR) at 6 months or more, and 56% of patients with DOR at 12 months or more